Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab for Sclerotic Chronic Graft-Versus-Host Disease
NCT07011810Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of axatilimab in chronic graft-versus-host disease (cGVHD), sponsored by Fred Hutchinson Cancer Center. Started Aug 2025; status: recruiting.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT07011810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011810.